Please assess the completion status of the following clinical trial:

Trial Title: Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Stage I~* Participant is healthy, as determined by medical history and physical examination.~* Participant is at least 3 years of age but not yet 6 years of age at the enrolment.~* For the TetraMenD group: received one dose of TetraMenD as a participant in trial 603-02 no less than 18 months prior to enrolment~* For the Control group: no previous history of any meningococcal vaccination~* Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.~* Stage II~* Participant is healthy, as determined by medical history and physical examination.~* Participant is at least 3 years of age but not yet 6 years of age at the time of enrollment in Stage 1.~* Enrolled in the Control group only and received one dose of the reduced dose Menomune at Stage 1.~* Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.~Exclusion Criteria :~* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc.)~* Known or suspected impairment of immunologic function~* Acute medical illness with or without fever within the last 72 hours or an axillary temperature (≥ 99.5ºF \[≥ 37.5ºC\]) at the time of inclusion~* For Stage I, history of documented invasive meningococcal disease or previous meningococcal vaccination with exception of those participants recruited from Trial 603-02.~* For Stage II, history of documented invasive meningococcal disease or participant did not receive Reduced-dose Menomune® six months prior.~* Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.~* Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn~* Received any vaccine in the 28-day period prior to study vaccination, or scheduled to receive any vaccination during the 28-day period after study vaccination in Stage 1 of the trial.~* Suspected or known hypersensitivity to any of the vaccine components~* Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures~* Enrolled in another clinical trial~* Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Previously received TetraMenD (Type: EXPERIMENTAL): Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
- Meningococcal vaccine-naїve (Type: EXPERIMENTAL): Participants have never received a Meningococcal vaccine in the past.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete